These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19909879)

  • 1. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
    Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
    J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
    Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
    Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambrisentan therapy for pulmonary arterial hypertension.
    Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
    J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.
    Blalock SE; Matulevicius S; Mitchell LC; Reimold S; Warner J; Peshock R; Torres F; Chin KM
    J Card Fail; 2010 Feb; 16(2):121-7. PubMed ID: 20142023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
    Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
    Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
    Klinger JR; Oudiz RJ; Spence R; Despain D; Dufton C
    Am J Cardiol; 2011 Jul; 108(2):302-7. PubMed ID: 21545989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
    Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
    Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambrisentan.
    Croxtall JD; Keam SJ
    Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ambrisentan for the management of pulmonary arterial hypertension.
    Cheng JW
    Clin Ther; 2008 May; 30(5):825-33. PubMed ID: 18555930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
    Badesch DB; Feldman J; Keogh A; Mathier MA; Oudiz RJ; Shapiro S; Farber HW; McGoon M; Frost A; Allard M; Despain D; Dufton C; Rubin LJ;
    Cardiovasc Ther; 2012 Apr; 30(2):93-9. PubMed ID: 21884013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.
    Peacock AJ; Zamboni W; Vizza CD
    Curr Med Res Opin; 2015; 31(9):1793-807. PubMed ID: 26196225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
    Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambrisentan.
    Frampton JE
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):215-26. PubMed ID: 21623643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of pulmonary arterial hypertension: role of ambrisentan.
    Barst RJ
    Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
    Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
    N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
    Kingman M; Ruggiero R; Torres F
    Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension.
    Cartin-Ceba R; Swanson K; Iyer V; Wiesner RH; Krowka MJ
    Chest; 2011 Jan; 139(1):109-14. PubMed ID: 20705798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
    Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.